Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 51

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
520 Intangible AssetsIntangible assets, net, consists of the in-process research and development, or IPR&D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition are summarized as follows (dollar amounts in thousands):March 31, 2025Gross Carrying ValueForeign currency adjustmentsAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $— $(213,254)$376,746 10 years, 5 monthsCustomer relationships90 — (54)36 10 yearsTotal finite-lived intangible assets, net590,090 — (213,308)376,782 Acquired IPR&D57,366 821 — 58,187      Total intangible assets, net$647,456 $821 $(213,308)$434,969 December 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $(198,934)$391,066 10 years, 5 monthsCustomer relationships90 (52)38 10 years     Total finite-lived intangible assets, net590,090 (198,986)391,104 Acquired IPR&D34,866 — 34,866      Total intangible assets, net$624,956 $(198,986)$425,970 Amortization expense on intangible assets was $14.3 million for both the three months ended March 31, 2025 and 2024.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 16

Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $43.0 million for the remaining nine months of 2025, $57.3 million each year from 2026 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.

NOTE 9—DEBT

The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):March 31,